Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2003

View Archived Issues

New CCR3 antagonists and their use described by Toray and Yamanouchi

AstraZeneca presents four novel series of CDK inhibitors

Preparation and use of neurotrophin inhibitors reported by JT team

New factor Xa inhibitors covered by Curacyte patent

BMS scientists discover novel CCR2 antagonists for asthma, multiple sclerosis, arthritis, etc.

Osteogenesis promoters and their use claimed by Yamanouchi

Human Genome Sciences acquires IHC diagnostic rights for TRAIL-R1 and TRAIL-R2

Yamanouchi receives approvable letter for Vesicare

Diversa and Medarex form antibody engineering strategic partnership

Favrille raises financing to support phase II and III trials of FavId for NHL

First NMDA receptor antagonist approved by FDA for Alzheimer's disease

Approval received to commence Canadian FluINsure field trial

Locus licenses novel gp41 crystal structure

Metabasis receives SBIR grant for efforts in hepatitis C

deCODE identifies genetic risk factors for heart attack

Speedel's new renin inhibitors show efficacy for hypertension, renal disease

Recent clinical development highlights at Tularik

Encouraging six-month results from phase II study of merimepodib in HCV

Pegasys approved in Japan

Pintex publishes data supporting Pin1 as a prognostic marker and therapeutic target in cancer

Japanese approval obtained for first-in-class antibiotic for community-acquired RTIs

Regulated hypothermia induced in rats by the neurotensin analogue NT-77

KIT as a potential target for postradiation sarcoma

Promising pharmacokinetic and safety data reported for a propofol prodrug in humans

Vasodilating effects of topical methyl nicotinate in diabetic patients

Comparison of CVT-3146 and adenosine as agents for pharmacological stress testing

AL-2512 as a potentially safer ocular antiinflammatory agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...